Biomarin Pharmaceutical Inc (BMRN)

Activity ratios

Short-term

Turnover ratios

Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019
Inventory turnover 0.45 0.47 0.50 0.52 0.55 0.54 0.57 0.58 0.59 0.61 0.64 0.79 0.75 0.75 0.70 0.54 0.54 0.53 0.56 0.55
Receivables turnover 3.83 3.74 3.95 3.58 3.55 4.46 4.76 4.08 4.35 4.89 4.88 4.46 4.58 4.07 4.43 4.76 4.47 4.49 3.96 4.03
Payables turnover — — — — — — — — — — — — — — — — — — — —
Working capital turnover 1.29 1.33 1.26 0.93 0.95 0.95 0.92 0.93 0.98 1.06 1.02 0.99 0.98 0.99 0.97 0.99 1.37 1.68 1.17 1.11

Inventory turnover ratios for Biomarin Pharmaceutical Inc have been relatively stable over the periods, ranging from 0.45 to 0.79. This indicates that the company is efficient in managing its inventory levels, with a lower ratio suggesting slower turnover and potentially excess inventory.

Receivables turnover ratios have also been consistent, fluctuating between 3.55 and 4.89. A higher receivables turnover ratio suggests that the company is collecting its receivables more quickly, which is positive for cash flow management.

Payables turnover data is missing from the table, so it is unclear how quickly the company is paying its suppliers.

The working capital turnover ratios have shown some variation, ranging from 0.92 to 1.68. A higher turnover indicates that the company is efficiently utilizing its working capital to generate sales revenue.

Overall, Biomarin Pharmaceutical Inc appears to have reasonably efficient activity ratios, particularly in inventory and receivables turnover, which reflect effective management of assets and working capital.

Average number of days

Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019
Days of inventory on hand (DOH) days 808.91 771.55 730.70 702.13 667.91 674.72 643.53 631.98 614.19 602.50 573.56 461.62 488.84 486.33 517.80 675.07 674.85 690.75 656.56 659.03
Days of sales outstanding (DSO) days 95.20 97.47 92.40 101.95 102.79 81.76 76.60 89.45 83.89 74.58 74.80 81.89 79.64 89.78 82.46 76.73 81.61 81.30 92.07 90.63
Number of days of payables days — — — — — — — — — — — — — — — — — — — —

Biomarin Pharmaceutical Inc's days of inventory on hand (DOH) have shown a fluctuating trend over the past five quarters, ranging from 573.56 days to 808.91 days. This indicates variations in the efficiency of managing inventory levels. A higher DOH may imply slow-moving inventory or potential obsolescence, while a lower DOH could suggest potential stockouts impacting sales.

Days of sales outstanding (DSO) for Biomarin Pharmaceutical Inc have also experienced fluctuations over the same period, ranging from 74.58 days to 102.79 days. This indicates variability in the company's ability to collect receivables from customers. A higher DSO may indicate credit or collection issues, impacting cash flow, while a lower DSO could imply effective credit management.

Information on the number of days of payables is not available, so the analysis of payment efficiency is limited. However, tracking this metric in the future could provide insights into Biomarin's ability to manage its cash flow by optimizing payment terms with suppliers.

Overall, Biomarin Pharmaceutical Inc should focus on optimizing its inventory levels, streamlining its accounts receivable collection process, and monitoring payment terms with suppliers to enhance operational efficiency and cash flow management.

Long-term

Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019
Fixed asset turnover 2.30 2.23 2.12 2.05 1.99 1.92 1.90 1.81 1.80 1.76 1.79 1.84 1.78 1.77 1.80 1.79 1.76 1.68 1.65 1.58
Total asset turnover 0.36 0.35 0.33 0.33 0.33 0.32 0.32 0.31 0.31 0.30 0.31 0.32 0.31 0.31 0.30 0.34 0.38 0.36 0.35 0.35

Biomarin Pharmaceutical Inc's fixed asset turnover ratio has shown a consistent improvement over the past five quarters, increasing from 1.58 in Q2 2019 to 2.30 in Q1 2024. This indicates that the company is generating more revenue from its fixed assets over time.

On the other hand, the total asset turnover ratio has fluctuated slightly but generally remained within a narrow range, with a slight increase from 0.30 in Q2 2019 to 0.36 in Q1 2024. This ratio signifies how efficiently the company is utilizing all its assets to generate revenue.

The improvement in the fixed asset turnover ratio suggests that Biomarin Pharmaceutical Inc is managing its fixed assets more effectively, potentially through better utilization or increased productivity. However, the relatively stable trend in the total asset turnover ratio indicates that the company's overall asset management efficiency has been consistent.

Overall, the increase in both fixed asset turnover and total asset turnover ratios suggests that Biomarin Pharmaceutical Inc has been adept at optimizing its asset utilization, which could positively impact its financial performance and profitability in the long term.